Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
R&D
R&D
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
FDA orphan drug and rare pediatric disease designations granted to Arbor Biotechnologies’ primary hyperoxaluria type 1 treatment
Relmada Therapeutics acquires potential Tourette syndrome therapy from Asarina Pharma
Vanda Pharmaceuticals and AnaptysBio announce global license agreement for Generalized Pustular Psoriasis treatment
hVIVO signs RSV human challenge trial contract with Inhalon Biopharma
4th February 2025
Orion and Invenra to develop innovative bispecific antibody cancer therapeutics
3rd February 2025
Beacon granted FDA Regenerative Medicine Advanced Therapy designation for X-linked retinitis...
30th January 2025
hVIVO acquires two Clinical Research Units from CRS for €10m
29th January 2025
GSK and University of Oxford collaborate to advance novel cancer research
28th January 2025
Cancer Research Horizons and Lifebit to maximise impact of research data
28th January 2025
AbbVie and Neomorph to develop molecular glue degraders for oncology and...
27th January 2025
Zai Lab receives U.S. FDA Orphan Drug Designation for small cell...
24th January 2025
Cancer Research UK, Cytovation and the Norwegian Cancer Society to advance...
23rd January 2025
Multi-million Euro research initiative to use biomarkers to transform Crohn’s Disease
22nd January 2025
1
2
3
...
54
Page 1 of 54
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...